FUJIFILM Biosciences, a global life sciences company, along with NextCell Pharma AB, a cell therapy company, released a new global product together. It includes FUJIFILM’s PRIME-XV MSC Expansion XSFM media and NextCell’s NextCell-Cord RUO, a research-use-only product made from umbilical cord cells.
MSC research can be hard because the cells are not always the same, may not match the immune system, and are hard to make. NextCell-Cord RUO gives researchers a more consistent and easier-to-use source of cells. With FUJIFILM’s media, it provides a high-quality solution for research in immunology, regenerative medicine, and cell therapy.
NextCell-Cord RUO is now available worldwide through FUJIFILM Biosciences, either on its own or bundled with the media, growth factors, and reagents.
According to Coherent Market Insights, the Cell Therapy Market is expected to grow at a CAGR of 9.8% from 2026 to 2033. Currently, the market is at USD 3,109.6 Mn in 2026 and is expected to be around USD 5,983.1 Mn by 2033. The global cell therapy market is rapidly expanding as advancements in regenerative medicine, immunotherapy, as well as genetic engineering drive innovation. Researchers and companies are developing therapies such as CAR-T cells, stem cells, TCR therapies, etc., to treat oncology, rare diseases, and autoimmune disorders.
"FUJIFILM Biosciences is committed to paving a better way forward with life science products, services, and solutions that serve the evolving needs of our academia, biotech, and pharmaceutical partners worldwide," said Brandon Pence, president and chief operations officer at FUJIFILM Biosciences. "Our strategic alliance with NextCell Pharma further strengthens our commitment to enabling our customers to achieve more with products and solutions they need every day to help create a healthier world for all."
"We've worked with FUJIFILM Biosciences to ensure that this product meets the needs of researchers and drug developers who value consistency, scalability, and translational relevance," said Dr. Lindsay Davies, chief scientific officer at NextCell Pharma AB. "NextCell-Cord RUO reflects not only our clinical manufacturing expertise, but also a commitment to delivering high-quality, standardized MSC products that are scientifically robust and immediately usable in research and development workflows."
